Sirna Says It s On Track for Clinical Trials of RNAi Next Year Amid Q2 Report; CombiMatrix Launches Gene Silencing Service; Dharmacon Introduces New, Improved SiRNAs | GenomeWeb

NEW YORK, Aug. 18 (GenomeWeb News) - About a year after reinventing itself as an RNAi company, Sirna Therapeutics (formerly Ribozyme Pharmaceuticals) appears to have gotten back into the swing of things.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.